Document is current
Any future updates will be listed below
-
Authors
Ranek, Mark J.
Oeing, Christian
Sanchez-Hodge, Rebekah
Kokkonen-Simon, Kristen M. https://orcid.org/0000-0001-8449-9088
Dillard, Danielle
Aslam, M. Imran
Rainer, Peter P. https://orcid.org/0000-0002-2840-6454
Mishra, Sumita
Dunkerly-Eyring, Brittany
Holewinski, Ronald J.
Virus, Cornelia
Zhang, Huaqun
Mannion, Matthew M.
Agrawal, Vineet
Hahn, Virginia
Lee, Dong I.
Sasaki, Masayuki
Van Eyk, Jennifer E. https://orcid.org/0000-0001-9050-148X
Willis, Monte S.
Page, Richard C. https://orcid.org/0000-0002-3006-3171
Schisler, Jonathan C. https://orcid.org/0000-0001-7382-2783
Kass, David A. https://orcid.org/0000-0003-1596-2299
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (OE 688/1-1)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F31-HL134196, T32-HL-07227, F31-HL143905, T32-HL-07227)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG061188)
- License Information
-
More Information
Article History
Received: 16 December 2019
Accepted: 23 September 2020
First Online: 20 October 2020
Competing interests
: Dr. Ranek and Kass are co-inventors of a provisional patent related to the use of CHIP phosphomutants for gene therapy of protein quality control-aggregation disorders. The remaining authors declare no competing interests.
